Probing the Conformation States of Neurotensin Receptor 1 Variants by NMR Site-Directed Methyl Labeling by Goba, Inguna et al.








Probing the Conformation States of Neurotensin Receptor 1 Variants by
NMR Site-Directed Methyl Labeling
Goba, Inguna ; Goricanec, David ; Schum, Dominik ; Hillenbrand, Matthias ; Plückthun, Andreas ;
Hagn, Franz
Abstract: G protein-coupled receptors (GPCRs) are key players in mediating signal transduction across
the cell membrane. However, due to their intrinsic instability, many GPCRs are not suitable for structural
investigations. Various approaches have been developed in recent years to remedy this situation, ranging
from the use of more native membrane mimetics to protein-stabilization methods. The latter approach
typically results in GPCRs that contain various numbers of mutations. However, probing the functionality
of such variants by in vitro and in vivo assays is often time consuming. In addition, to validate the
suitability of such GPCRs for structural investigations, an assessment of their conformation state is
required. NMR spectroscopy has been proven to be suitable to probe the conformation state of GPCRs in
solution. Here, by using chemical labeling with an isotope-labeled methyl probe, we show that the activity
and the conformation state of stabilized neurotensin receptor 1 variants obtained from directed evolution
can be efficiently assayed in 2D NMR experiments. This strategy enables the quantification of the active
and inactive conformation states and the derivation of an estimation of the basal as well as agonist-induced
activity of the receptor. Furthermore, this assay can be used as a readout when re-introducing agonist-
dependent signaling into a highly stabilized, and thus rigidified, receptor by mutagenesis. This approach
will be useful in cases where low production yields do not permit the addition of labeled compounds to
the growth medium and where 1D NMR spectra of selectively 19 F-labeled receptors are not sufficient to
resolve signal overlap for a more detailed analysis.
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Probing the Conformation States of Neurotensin Receptor
1 Variants by NMR Site-Directed Methyl Labeling
Inguna Goba,[a] David Goricanec,[b] Dominik Schum,[b] Matthias Hillenbrand,[c]
Andreas Plückthun,[c] and Franz Hagn*[a, b]
G protein-coupled receptors (GPCRs) are key players in media-
ting signal transduction across the cell membrane. However,
due to their intrinsic instability, many GPCRs are not suitable for
structural investigations. Various approaches have been devel-
oped in recent years to remedy this situation, ranging from the
use of more native membrane mimetics to protein-stabilization
methods. The latter approach typically results in GPCRs that
contain various numbers of mutations. However, probing the
functionality of such variants by in vitro and in vivo assays is
often time consuming. In addition, to validate the suitability of
such GPCRs for structural investigations, an assessment of their
conformation state is required. NMR spectroscopy has been
proven to be suitable to probe the conformation state of GPCRs
in solution. Here, by using chemical labeling with an isotope-
labeled methyl probe, we show that the activity and the
conformation state of stabilized neurotensin receptor 1 variants
obtained from directed evolution can be efficiently assayed in
2D NMR experiments. This strategy enables the quantification
of the active and inactive conformation states and the
derivation of an estimation of the basal as well as agonist-
induced activity of the receptor. Furthermore, this assay can be
used as a readout when re-introducing agonist-dependent
signaling into a highly stabilized, and thus rigidified, receptor
by mutagenesis. This approach will be useful in cases where
low production yields do not permit the addition of labeled
compounds to the growth medium and where 1D NMR spectra
of selectively 19F-labeled receptors are not sufficient to resolve
signal overlap for a more detailed analysis.
G protein-coupled receptors (GPCRs) are important conforma-
tional switches in signal transduction across the cell membrane.
The conformation state of a GPCR determines whether it is able
to act as a guanine nucleotide exchange factor (GEF) on bound
heterotrimeric G proteins. The analysis of the conformational
transition between the inactive to the active state of a GPCR
has been a subject of continuing efforts using structural
methods.[1] Possible conformation states occurring along the
activation process have been described recently.[2] There are
two inactive states (S1 and S2) where the transmembrane helix
6 (TM6) is either tightly bound to the helical bundle or more
mobile. Binding of the agonist increases the population of an
intermediate state that is more mobile in the cytoplasmic part
(S3 state), and this state becomes further opened and stabilized
by binding to the G protein (S4 state). For high-resolution
structural investigations by crystallography or cryo-EM, this
cytoplasmic stabilization can also be achieved by binding to
G protein fragments or a G protein mimetic.[3] NMR spectro-
scopy has been successfully used to probe ligand-dependent
conformational changes even without stabilizing binding
partners, and it turned out to be a powerful tool for capturing
slight changes in the populations of various states modulated
by small molecule ligands and nanobody G protein mimetics.[4]
Since many GPCRs are very unstable and cannot be produced
in sufficient amounts for structural investigations, various
approaches have been introduced to optimize their biophysical
properties. In order to remedy stability issues, the use of a
native lipid nanodisc environment[5] has been shown to increase
thermodynamic as well as long-term stability of a GPCR.[6]
However, in order to resolve protein production issues, the
GPCR itself needs to be modified. This has been achieved with
systematic mutagenesis[7] or directed evolution.[8] Either of these
approaches results in GPCRs that contain a varying number of
mutations, raising concerns about the functionality of such
stabilized GPCRs in general, or conversely, losing stability again.
Thus, functional assays need to be conducted to probe the
activity profile of each receptor variant. A prominent model
system subjected to protein stabilization methods is the rat
neurotensin receptor subtype 1 (rNTR1). While its successful
production in Escherichia coli was described decades ago,[9] the
overall yields and stability of the wild-type receptor were still
too low for X-ray crystallographic structural studies. X-ray
structures of neurotensin-bound rNTR1 could eventually be
determined with stabilized receptor variants.[10] More recently, a
structure of wild-type human NTR1 in complex with a
heterotrimeric G protein could be determined by cryo-EM.[3a]
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Despite the apparent benefit of stabilized GPCRs for structural
investigations it is essential to be able to assess their
functionality in a reliable and quick manner. In particular, a
more detailed estimation of the conformational equilibrium
between the inactive and active state of a GPCR variant is
highly beneficial to guide and motivate more detailed and
time-consuming structural and dynamical investigations with
NMR spectroscopy.
Here, we used NMR spectroscopy to determine the ligand-
dependent conformational equilibria of stabilized rNTR1 var-
iants, which is in very good agreement with biochemical GEF
activity assay data. In order to record 2D 1H,13C correlation
experiments to resolve NMR signals of the inactive and active
states of the GPCR, we modified surface-accessible cysteine
residues in each rNTR1 variant with an 13C-isotope-labeled
methyl tag. These probes turned out to be suitable to monitor
changes in the conformational equilibrium of the receptor at
the cytoplasmic G protein binding site induced by either an
agonist or an antagonist ligand. After initial validation of the
NMR results with functional assay data, we performed a
systematic mutagenesis with a highly evolved rNTR1 variant
and used our NMR setup to determine which mutation in the
receptor is responsible for its markedly increased basal activity.
Finally, we discuss structure-activity relationships of the inter-
play between different mutations that might modulate the
activity of the receptor in a cooperative manner. This
experimental setup provides a fast and effective way to assay
the conformation state of a GPCR in a ligand- or G protein-
dependent manner or for validation of stabilized receptors for
subsequent NMR studies on structure and dynamics.
Directed evolution[11] has been employed to obtain opti-
mized rNTR1 variants that can be produced in E. coli in high
yields. Among others, two variants (named TM86 V and HTGH4)
have been shown to be suitable for structure determination.[10b]
However, the employed evolutionary stabilization procedure
resulted in the stepwise accumulation of point mutations (11 in
TM86 V, 26 in HTGH4, Figure 1a,b). Thus, we here probed the
functionality of each receptor variant by G protein GTP
exchange stimulation assays in comparison with wild-type
rNTR1 (Figure 1c). With wild-type rNTR1, GTP exchange activity
is very low if the receptor is present in the apo form or bound
to the small molecule antagonist SR142948 (SR),[12] and highly
elevated in complex with the native agonist peptide neuro-
tensin (NT1), as expected for a functional GPCR with low basal
activity (black bars). The rNTR1 variant TM86 V with fewer
mutations, which has not been subjected to such a rigorous
selection pressure as HTGH4, shows an increased basal activity
but can still be stimulated in an agonist-dependent manner
(red bars). In order to ensure proper interaction of the GPCR
with the G protein, a L1673.50R back mutation (BM) had to be
introduced that reverts a leucine residue that has been
introduced by directed evolution back to a highly-conserved
arginine residue (Figure 1a). The highly evolved rNTR1 receptor
variant HTGH4-BM shows a markedly increased basal activity,
leading to a full GTP exchange signal in the chosen assay
conditions even without bound agonist. Apparently, the addi-
Figure 1. Point mutations and G protein stimulation activity of stabilized rNTR1 variants. a) TM86V contains 11 point mutations.[13] b) In HTGH4, 15 further
mutations are present from additional evolution for detergent stability.[14] c) G protein GTP exchange stimulation assay with wild-type rNTR1 (black bars),
TM86V-BM (red bars), HTGH4-BM (blue bars), and HTGH4 (green bars) in the apo form as well as bound to the peptide agonist NT1 or the small-molecule
antagonist SR. No data are available for TM86V-BM in complex with SR, n.a.: not available. d) Selected regions of a multiple sequence alignment of rNTR1,






























































tional mutations in HTGH4 lead to a striking increase in basal
activity in the presence of BM, but only a slight one in its
absence. Critical mutations are most likely inward-facing
positions where the amino acid side chains contribute to
packing of the α-helical bundle in the GPCR. A multiple
sequence alignment of wild-type rNTR1, TM86V and HTGH4 at
critical regions in the protein reveals changes in charge,
hydrophobic properties and chain length of amino acids by
mutation (Figure 1d).
Thus, we were interested in establishing a robust and
reliable setup to probe not only macroscopic activity but also
the conformation state of rNTR1 variants by solution-state NMR
spectroscopy in order to identify residues in HTGH4 that
contribute to its characteristic and non-selective activity profile.
In order to introduce NMR-active probes into rNTR1 variants, we
utilized the selective chemical modification of surface-exposed
cysteine residues. HTGH4 and TM86 V contain 3 or 4 surface-
accessible cysteine residues, respectively, at positions 1723.55,
3326.59 (TM86 V only), 386 and 388 (both in helix 8; Figure 2a). In
order to introduce a suitable probe close to the G protein
binding interface and to be able to monitor the conformational
change taking place upon GPCR activation, we introduced an
additional cysteine residue at the cytoplasmic end of TM6
(V3006.27C). This position has been previously utilized to probe
GPCR activation by fluorescence spectroscopy or 19F NMR.[4h,15]
The surface accessibility of the cysteines in HTGH4-V300 C was
confirmed by quantitative chemical modification yields with the
alkylating agent S-methyl-13C-methanethiosulfonate (MMTS),
resulting in modified cysteine side chains that contain a
disulfide-bridged and 13C isotope-labeled methyl tag, as
detected by ESI-mass spectrometry. The power of MMTS label-
ing for NMR has been demonstrated recently.[16] As shown in
Figure 2b, we were able to detect the correct mass that is
expected with 4 accessible cysteine residues in this rNTR1
variant. Similar results have been obtained with TM86V-V300C
containing five surface-exposed cysteines. The thermal stability
of both receptor variants is not affected by the chemical
modification, giving rise to a cooperative thermal unfolding
transition at 70 and 80 °C for TM86V and HTGH4, respectively
(Figure 2c). These data also suggest that the cooperativity of
thermal unfolding of TM86V is lower if in complex with the SR
antagonist, presumably caused by the lower degree of
evolution of this NTR1 variant as compared to HTGH4.
Next, we were interested to monitor the spectral features of
the two rNTR1 variants in n-dodecyl-β-d-maltoside (DDM)
micelles by 2D 13C,1H HMQC NMR experiments and probe the
effect of the stabilizing mutation R1673.50L, which introduces a
hydrophobic lock,[10b] but prevents G protein signaling. As
shown in Figure 3, high-quality spectra could be obtained with
13C-MMTS-labeled and otherwise natural abundance, i. e. non-
deuterated rNTR1 variants with the expected number of signals
in each case. It is expected that additional deuteration of the
receptor will further increase the NMR spectral quality. This is
only possible in very few chases, though. Assignment of the
NMR signals was achieved by mutagenesis of selected cysteine
residues in the protein (Figure S1 in the Supporting Informa-
tion), where 2D 13C,1H HMQC NMR spectra of HTGH4-BM,
HTGH4-BM C386S and HTGH4-BM V300C provided unambigu-
ous information that could be transferred to TM86V-BM. By
comparing the spectra of HTGH4V300C and HTGH4-BM V300C
in the agonist or antagonist-bound state we were able to obtain
valuable insights on the observed change in GPCR activity
(Figure 3a). With HTGH4V300C (containing L167), the spectra in
each ligand-bound state are almost identical, whereas the back
mutation (L167R) leads to appearance of multiple conformation
states and marked changes in the NMR peak intensity pattern
between the agonist- and antagonist-bound states. In this
variant, we observe pronounced line broadening effects for
position 172, indicating enhanced motions on the millisecond
to microsecond timescale. In order to obtain insights into
receptor stabilization by G protein binding, we added a peptide
derived from the C-terminal helix 5 of the G protein αi,1 subunit
(Gαi,1; Figure S2). This resulted in additional line broadening at
position 172 and a strong reduction of the intensity of the
signals of the inactive states at position 300 (Figure 3a).
Moreover, we observed the occurrence of two NMR signals for
the active state, which most likely represents the S3 and the
G protein-bound S4 states. By plotting the observed intensity
patterns along the indirect 13C dimension (Figure 3b), we could
visualize and assign each observed peak to an active or inactive
conformation state (S1 to S4[2]). The 2D NMR spectra of the
TM86V-BM V300C variant showed an additional NMR signal for
Cys332, as well as multiple sub-states that represent the
inactive or active conformations of the receptor, respectively
(Figure 3c).
Figure 2. Labeling of stabilized rNTR1 variants at accessible cysteine
positions with 13C-labeled MMTS. a) rNTR1 variants HTGH4 and TM86V
contain four or five solvent-accessible cysteine residues, respectively, that
can be labeled. C332 next to the NT1 peptide binding site is only present in
TM86V. b) ESI-MS confirms the correct number of four attached S 13CH3
labels in the case of HTGH4. c) CD-detected thermal stability analysis of 13C-
MMTS-labeled rNTR1 variants in complex with the agonist NT1 or the small-






























































In addition, changes in signal intensity could be observed
between the inactive and active states (Figure 3d), where in
particular the intensity of the signal at position 172 was
markedly weakened by line broadening in presence of an
agonist, which is a clear indication for altered dynamics upon
receptor activation. Furthermore, the addition of a peptide
derived from the C-terminal helix 5 of the G protein αi,1 subunit
(Gαi,1) (Figure S2) to
13C-MMTS-labeled TM86V-BM V300C re-
sulted in chemical shift perturbations and changes in signal
intensity where mostly the NMR signals corresponding to the
active state were affected, further corroborating the assignment
of the individual peaks to defined functional states (Figure 3c,d).
Figure 3. Probing the active state of rNTR1 variants by using 13C-MMTS labeling and 2D NMR spectroscopy in DDM micelles. a) 2D 13C,1H HMQC spectra of 13C-
MMTS-labeled rNTR1 variants in complex with an antagonist SR or agonist NT1 show marked differences. HTGH4, which harbors the ionic lock mutation
L1673.50 does not adopt active states at the intracellular side with a bound agonist, whereas the back mutation (BM) L1673.50R leads to an active receptor, as
indicated by the occurrence of a second signal for positions 300 and 172 that are located close to the G protein coupling interface. b) Slices of the spectra in
(a) along the 13C dimension, as indicated by broken lines, can be used for quantification and the assignment of the involved structural states, as visualized in
(e). c) 2D 13C,1H HMQC spectra of TM86 V-BM bound to an antagonist SR or agonist NT1 and in complex with a peptide derived from the C-terminal helix 5 of
Gα. Asterisks mark methyl signals from the Gα peptide at natural abundance. d) Slices along the 13C dimension of the spectra in (c). For TM86V-BM, an
additional inactive state at ~23.25 ppm 13C chemical shift as detected, consistent with a further inward rotation of TM6 at the intracellular side, was also
observed in the crystal structures of the antagonist-bound state.[18] e) Visualization of the structural states involved in GPCR activation, adapted from ref. [2]. f)






























































A quantification of the inactive versus active states at the
intracellular side in each of the shown receptor variants
provides a detailed picture of their ligand-dependent activity
profile (Figure 3e,f). In the NMR spectra of active rNTR1 variants,
we typically observe multiple peaks, similar to the observations
of Kobilka and colleagues with the β2 adrenergic receptor,
[2]
which allowed them to define sub-states occurring during
receptor activation. These four states could be later confirmed
using BLT2 receptor.[4e] Here, states S1 and S2 define the
inactive conformation, S3 the intermediate, active conformation
in the presence of agonist but without G protein, and S4 the
active state bound to a G protein (Figure 3e). For a simplified
analysis of the conformation states in rNTR1 variants we
summed up the populations of the inactive (S1+S2) and the
active states (S3+S4) for positions 1723.55 and 3006.27, respec-
tively, that are both located in close proximity to the G protein
binding site (Figure 3f). This analysis confirms the activity data
derived from biochemical assays (Figure 1c). HTGH4, without
the L167R back mutation, is always present in the inactive
conformation as monitored at the intracellular side, even in
complex with an agonist, consistent with the crystal structure of
this complex.[10b] For HTGH4-BM in complex with an antagonist
the basal activity is increased compared to HTGH4, and bound
to an agonist the relative population of the active state is
increased to almost 60%, which is further increased upon
complex formation with a G protein. This increased population
of the active state, even in the antagonist-bound state, is
consistent with the high basal activity of this receptor variant in
the GTP exchange assay with a bound G protein (Figure 1c). To
test whether antagonist-bound HTGH4-BM can still interact
with a G protein, we added the Gα peptide to MMTS-labeled
receptor in complex with SR142948 and observed pronounced
NMR spectral changes indicative of a pronounced stabilization
of the active states (Figure S3). In contrast, TM86 V-BM is almost
inactive in complex with an antagonist, and the agonist-
dependent final population of the active state reaches only
50%. Gα peptide binding generally leads to line broadening of
the NMR signals originating from the methyl groups at
positions 172 and 300, presumably caused by intermediate
chemical exchange processes. Among those, position 172
appears to be more affected than position 300, in particular in
the more active HTGH4-BM variant.
After the initial NMR characterization of the active states of
rNTR1 variants, which were in excellent agreement with the
biochemical GTP exchange assay, we were wondering what
mutations present in HTGH4-BM might cause the apparent
increase in basal activity that correlate with a strong decrease in
the ligand-dependent switching capability, present in a typical
wild-type GPCR. Thus, we designed a series of single-point
mutations in HTGH4-BM that lead to back mutations to the
wild-type amino acid type that is also present in TM86 V. We
selected five different positions (T1012.38R, D1242.61E, E1503.33D,
A2605.61I, R2625.63N/R2635.64K) that are located at the G protein
coupling site and at contact points between individual TMHs
(Figure 4a). It has been shown that the negative charge of
D1132.50, responsible for the Na+ sensitivity of agonist binding,
is crucial for switching to the active conformation in NTR1[17] as
well as in the Adenosine A2A receptor.
[4a] Mutation at this
position consequently leads to an inactive receptor. We there-
fore included the D1132.50S mutation as a negative control that
should not restore signaling. Simplified representations of the
structural states that can occur during GPCR activation are
shown in Figure 4b. The 1D NMR slices along the 13C dimension
of an 2D 13C,1H HMQC experiment for these six variants of
HTGH4-BM V300 C show pronounced differences in the pop-
ulations of the active and inactive states (Figure 4c). The 1D
slices for HTGH4-BM V300 C and TM86 V-BM V300 C are also
shown in the figure as a comparison. As expected, mutation of
D113 to serine decreased the population of the active states (S3
and S4) of the receptor to an almost undetectable level in
complex with both antagonist and agonist.
Interestingly, the receptor changes its conformation from
the fully inactive S1 state, seen in complex with an antagonist,
to the more dynamic S2 state when in complex with an agonist.
In the S2 state, TM6 of the receptor is less tightly bound to the
helical bundle of the GPCR (Figure 4b). However, due to the
missing switch residue D113, the transition to the active state
seems to be hindered, suggesting that a negative charge at the
contact region between TM3, TM6 and TM7 (Figure 5a) is
essential for a ligand-induced transition to the active state. The
back mutations at positions 101 and 262/263 caused a minor
change of the conformational profile of the receptor, where 101
leads to a slight increase in the active states if bound to an
antagonist and 262/263 to a decrease (Figure 4c). However,
positions 124, 150 and 260 were found to be more crucial for
rNTR1 activation. Mutation of Asp to Glu at position 124
resulted in a dramatic reduction in the population of the active
states if bound to an antagonist. Upon activation by an agonist,
mostly the states S2 and S3 were populated with an overall
relative population of the active states of 45%. The ligand-
dependent switching characteristics induced by this single-
point mutation in HTGH4-BM is cleaner than the profile
obtained with the less evolved TM86 V variant that also harbors
a Glu residue at position 124. This behavior highlights the
necessity to probe the conformation state of a receptor by rapid
structural readouts. The location of residue 124 in TM2 in the
structure of HTGH4 and TM86V suggests that the longer Glu
side chain is able to form a salt bridge with Arg149 located in
TM3, thus leading to a better interaction with the entire helical
bundle of the GPCR (Figure 5b). An opposite tendency was
observed with the E150D variant. In complex with an antago-
nist, all conformation states are present in the receptor to an
almost equal extent, suggesting less stringent conformational
switching. Bound to an agonist, this conformational equilibrium
is completely shifted towards the fully active state S4 (Fig-
ure 4c).
When comparing the HTGH4 and TM86V structures (Fig-
ure 5c), it appears that the longer side chain of Glu1503.33 in
HTGH4 forms a strong salt bridge with Arp3286.55, partially
hindering agonist-induced transition to the active state. This is
the case in HTGH4 but not in TM86 V, where the wild-type
Asp150 is retained. A Glu-mediated salt bridge at this position
enhances the interaction between TM3 and TM6 and con-






























































to the active state. In contrast, the negative charge of the
shorter Asp150 side chain, as well as the positive charge of
Asp328, may play an important role in agonist-induced receptor
activation, in agreement with functional characterization of the
D150A and R328M mutations in the wild-type receptor.[18] This
behavior highlights the complex interplay between various
regions in the GPCR that affect its conformational landscape in
a cooperative manner. Another important residue in TM86 V
that has been mutated in HTGH4 is Ile260. In HTGH4, a smaller
Ala side chain is present at this position, which most likely leads
to a reduced interaction between TM5 and TM6 (Figure 5d),
thus increasing the population of the active states of the
receptor (in the presence of L167R). Back mutation of this
residue in HTGH4 to Ile mainly affects the type and population
of the inactive states. While predominantly the more mobile
and active S2 state is present in HTGH4-BM in complex with an
antagonist, the A260I mutation enhances the interaction of TM6
with the helical bundle, leading to a markedly increased
population of the inactive S1 state (Figure 4c), even though
both active states S3 and S4 are still present. Upon activation
by an agonist, a shift in the populations takes place to S2 and
to the active S3 and S4 states. A summary of the investigated
variants and their antagonist and agonist-dependent popula-
tions of the active and inactive conformation states is shown in
Figure 4d. In such a visualization, a wild-type-like GPCR should
show a small grey and a large red section, indicating low
population of the active states in complex with an antagonist
and strong boost in activity induced by binding to an agonist.
For both, HTGH4 and HTGH4-BM V300 C containing the D113S
mutation, an almost undetectable population of the active
states and in addition no agonist-dependent activation can be
observed, confirming that these variants cannot undergo the
conformational change at the intracellular side required for
functional G protein binding, even in the presence of agonist,
consistent with the nucleotide exchange results. HTGH4-BM, as
well as the R101T and the E150D variants show very high
Figure 4. Modulation of ligand-induced rNTR1 conformation states by mutagenesis. a) Single-point mutations (to the wild-type residue type) that have been
introduced into the HTGH4-BM V300C variant of rNTR1. b) Visualization of the structural states that could be monitored by NMR. c) Slices of 2D 13C,1H HMQC
spectra of the MMTS resonance at position 300 of the rNTR1 variants shown in (a); red: bound to the agonist NT1, grey: bound to the antagonist SR142948. d)






























































populations of the active conformation states in complex with
the antagonist but can still be further activated by an agonist,
suggesting G protein stimulation activity even in the antago-
nist-bound form (Figure 1c). Variants A260I and R262N/R263K
show a lower population of the active states with a bound
antagonist and lower total activity in complex with the agonist.
These features are similar to what has been measured with
TM86 V, which carries fewer mutations. However, the most
pronounced effect can be seen with the D124E variant of
HTGH4-BM, where the active states are barely populated in
complex with an antagonist, as also seen for the inactive
variants HTGH4 and HTGH4-BM D113S, but the agonist-induced
increase in the active states is as high as with HTGH4-BM. These
characteristics bring HTGH4-BM D124E closer to those of a wild-
type GPCR, which needs to display a low basal activity but high
activation by an agonist, yet maintain stability beyond that of
the wild-type, which is a prerequisite for functional and
structural studies (Figure 1c). Interestingly, this mutant also has
a wider activation window than TM86 V. These results also
emphasize the use of the presented NMR assay to probe the
conformational landscape of a stabilized GPCR and apply this
technology to rationally screen for gain-of-function variants, in
the context of a stable variant, by mutagenesis.
In summary, we have presented a 2D NMR-based approach
to monitor the conformation states of a stabilized rNTR1 based
on the chemical modification of intrinsic or engineered surface-
exposed cysteine residues with isotope-labeled methyl tags.
Due to the ability to record 2D 1H,13C HMQC experiments we
could resolve signal overlap and capture the NMR signals of
relevant conformation states in the receptor. Furthermore,
using G protein stimulation profiles of two rNTR1 variants
together with their 3D crystal structures, we were able to
rationally design a set of point mutations and probe their effect
on the population of the active or inactive conformation states
at the intracellular side using the described method. This
protocol facilitates the targeted functional rescue of stabilized
GPCRs and can be used to rationally design receptor variants
that can be produced in bacterial hosts in high yields and have
functional signatures similar to the original wild-type GPCR,
representing a major bottleneck in NMR-based structural
biology of this highly important protein class.
Experimental Section
All experimental details on protein design, mutagenesis, protein
production and purification, assays, as well as MMTS labeling and
biophysical and NMR methods are described in the Supporting
Information.
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